Join
Live feed
·
PRReleasevia Quantisnow
Aptose Biosciences Inc. logo

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

ByQuantisnow·Wall Street's wire, on your screen.
APTO· Aptose Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APTO (Aptose Biosciences Inc.) and more on Quantisnow.